NR4A1 and breast cancer: A more recent study from Indonesia analysing 115 young breast cancer patients showed a shorter progression-free survival in those with T4 tumours (16 versus 35 months), positive lymph nodes (24 versus 42 months), hormone receptor-positive (29 versus 24 months) and TNBC subtype (16 versus 38 months).